# US 8,278,274 B2 · Fibrin-binding peptides and conjugates thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,274 B2
- Document ID: US8278274B2
- Status: Granted
- Kind: B2
- Application number: 12/517,239
- Filed: 2007-12-11
- Published: 2010-06-24
- Granted: 2012-10-02
- Earliest claimed: 2006-12-11
- Assignees: Bracco Imaging S.P.A.
- Inventors: Philippe Bussat; Bernard Lamy; Edmund R. Marinelli; Sibylle Pochon; Bo Song; Rolf E. Swenson
- Web page: https://patentgrep.com/patent/US8278274B2

## CPC

- A61K 49/14: Peptides, e.g. proteins
- A61K 49/0043: {Fluorescein, used in vivo}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 49/085: {conjugated systems}
- A61K 49/124: {dendrimers, dendrons, hyperbranched compounds}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- G01N 33/532: Production of labelled immunochemicals
- G01N 33/575: for cancer
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging, etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof.

## Claims

### Claim 1

An isolated fibrin-binding peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:1 to 16, SEQ ID NOS:19-86, SEQ ID NOS:88-94, SEQ ID NOS:96-121 and SEQ ID NOS:134-135.

### Claim 2

An isolated fibrin-binding peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:1-2 and SEQ ID NOS: 134-135.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising a fibrin-binding peptide of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, further comprising a pharmaceutically acceptable ingredient, excipient, carrier, adjuvant or vehicle.

### Claim 5 (depends on 1)

A diagnostic imaging agent comprising at least one of the fibrin-binding peptides recited in claim 1, wherein said fibrin binding peptide is linked to a detectable label, optionally via a linker or a spacer.

### Claim 6 (depends on 5)

The diagnostic imaging agent of claim 5, wherein said agent is adapted for use in a modality selected from the group consisting of: magnetic resonance imaging, nuclear imaging, ultrasound imaging, x-ray imaging, and optical imaging.

### Claim 7 (depends on 6)

The diagnostic imaging agent of claim 6, wherein said agent is adapted for use in optical imaging.

### Claim 8 (depends on 7)

The diagnostic imaging agent of claim 7, wherein the detectable label is selected from the group consisting of dye molecules, fluorescent molecules, phosphorescent molecules, molecules absorbing in the UV spectrum, a quantum dot, and molecules capable of absorption within near or far infrared radiations.

### Claim 9 (depends on 8)

The diagnostic imaging agent of claim 8, wherein the fibrin binding peptide is linked to the detectable label via a linker.

### Claim 10 (depends on 8)

The diagnostic agent of claim 8, wherein the detectable label is a molecule capable of absorption within near infrared radiation selected from the group consisting of Cy5.5, IRDye800, indocyanine green (ICG), tetrasulfonic acid substituted indocyanine green (TS-ICG), and combinations thereof.

### Claim 11 (depends on 8)

The diagnostic agent of claim 8, wherein the detectable label is a dye molecule consisting of an organic chromophore or fluorophore having extensive delocalized ring systems and having absorption or emission maxima in the range of 400-1500 nm.

### Claim 12 (depends on 8)

The diagnostic imaging agent of claim 8, wherein the detectable label is a fluorescent molecule.

### Claim 13 (depends on 5)

The diagnostic imaging agent of claim 5, wherein said agent is adapted for use in ultrasound imaging.

### Claim 14 (depends on 5)

The diagnostic imaging agent of claim 5, wherein said agent comprises gas-filled microvesicles.

### Claim 15 (depends on 14)

The diagnostic imaging agent of claim 14, wherein said microvesicles comprise gas-filled microbubbles.

### Claim 16 (depends on 1)

A peptide-phospholipid conjugate comprising a fibrin-binding peptide of claim 1 and a phospholipid.

### Claim 17 (depends on 16)

The peptide-phospholipid conjugate of claim 16 wherein the phospholipid is selected from the group consisting of: distearoyl phosphatidyl-ethanolamine (DSPE) and dipalmitoyl phosphatidylethanolamine (DPPE).

### Claim 18 (depends on 16)

The peptide-phospholipid conjugate of claim 16 wherein the phospholipid is pegylated.

### Claim 19 (depends on 18)

The peptide-phospholipid conjugate of claim 18 wherein the pegylated phospholipid is selected from the group consisting of: distearoyl phosphatidyl-ethanolamine-polyethylene glycol 2000 (DSPE-PEG2000) and dipalmitoyl phosphatidylethanolamine-polyethylene glycol 2000 (DPPE-PEG2000).

### Claim 20 (depends on 16)

The peptide-phospholipid conjugate of claim 16 wherein the peptide and phospholipid are attached by a linking group.

### Claim 21 (depends on 20)

The peptide-phospholipid conjugate of claim 20 wherein the linking group comprises a moiety selected from the group consisting of: hydrophilic polymers and an amino acid chain.

### Claim 22 (depends on 21)

The peptide-phospholipid conjugate of claim 21 wherein the hydrophilic polymer is polyethylenglycol.

### Claim 23 (depends on 21)

The peptide-phospholipid conjugate of claim 21 wherein the amino acid chain comprises proline.

### Claim 24 (depends on 16)

An ultrasound contrast agent comprising a peptide-phospholipid conjugate of claim 16.

### Claim 25 (depends on 24)

The ultrasound contrast agent of claim 24, wherein the contrast agent comprises a gas-filled microvesicle.

### Claim 26 (depends on 25)

The ultrasound contrast agent of claim 25, wherein the gas filled microvesicle comprises a phospholipid.

### Claim 27 (depends on 26)

The ultrasound contrast agent of claim 26, wherein the phospholipid is selected from the group consisting of: distearoyl-phosphatidylcholine (DSPC), dipalmitoyl-phosphatidylglycerol (DPPG), DPPE, distearolyphosphatidylglycerol (DSPG), and distearoyl phosphatidic acid (DSPA).

### Claim 28 (depends on 25)

The ultrasound contrast agent of claim 25, wherein the gas-filled microvesicle comprises two or more components selected form the group consisting of: DSPC, DPPG, dipalmitoyl phosphatidic acid (DPPA), DSPA, DPPE, DSPG, polethyleneglycol1000 (DSPE-PEG1000) DSPE-PEG2000, palmitic acid and stearic acid.

### Claim 29 (depends on 26)

The ultrasound contrast agent of claim 26, wherein the gas is selected from the group consisting of: air, nitrogen, oxygen, CO2, hydrogen, nitrous oxide, a noble or inert gas, a radioactive gas, a hyperpolarized noble gas, a fluorinated gas, a low molecular weight hydrocarbon, a cycloalkane, an alkene, an alkyne, an ether, a ketone, an ester, a halogenated gas and mixtures thereof.

### Claim 30 (depends on 29)

The ultrasound contrast agent of claim 29, wherein the gas comprises a fluorinated gas.

### Claim 31 (depends on 30)

The ultrasound contrast agent of claim 30, wherein the gas is a mixture of C4F10 and nitrogen.

### Claim 32 (depends on 26)

The ultrasound contrast agent of claim 26 further comprising a therapeutic agent.

### Claim 33 (depends on 1)

An ultrasound contrast agent comprising at least one fibrin-binding peptide of claim 1.

### Claim 34 (depends on 33)

The ultrasound contrast agent of claim 33, wherein the contrast agent comprises a gas filled microvesicle.

### Claim 35 (depends on 34)

The ultrasound contrast agent of claim 34, wherein the gas filled microvesicle comprises a phospholipid.

### Claim 36 (depends on 35)

The ultrasound contrast agent of claim 35, wherein the phospholipid is selected form the group consisting of dilauryloyl-phosphatidylcholine (“DLPC”), dimyristoylphosphatidylcholine (“DMPC”), dipalmitoyl-phosphatidylcholine (“DPPC”), diarachidoylphosphatidylcholine (“DAPC”), DSPC, 1-myristoyl-2-palmitoylphosphatidylcholine (“MPPC”), 1-palmitoyl-2-myristoylphosphatidylcholine (“PMPC”), 1-palmitoyl-2-stearoylphosphatidylcholine (“PSPC”), 1-stearoyl-2-palmitoyl-phosphatidylcholine (“SPPC”), dioleoylphosphatidylycholine (“DOPC”), 1,2 Distearoyl-sn-glycero-3-Ethylphosphocholine (Ethyl-DSPC), dilauryloyl-phosphatidylglycerol (“DLPG”) and its alkali metal salts, diarachidoylphosphatidylglycerol (“DAPG”) and its alkali metal salts, dimyristoylphosphatidylglycerol (“DMPG”) and its alkali metal salts, DPPG and its alkali metal salts, DSPG and its alkali metal salts, dioleoylphosphatidylglycerol (“DOPG”) and its alkali metal salts, dimyristoyl phosphatidic acid (“DMPA”) and its alkali metal salts, dipalmitoyl phosphatidic acid DPPA and its alkali metal salts, DSPA, diarachidoyl phosphatidic acid (“DAPA”) and its alkali metal salts, dimyristoyl phosphatidyl-ethanolamin-e (“DMPE”), DPPE, DSPE, dimyristoyl phosphatidylserine (“DMPS”), diarachidoyl phosphatidylserine (“DAPS”), dipalmitoyl phosphatidylserine (“DPPS”), distearoylphosphatidylserine (“DSPS”), dioleoylphosphatidylserine (“DOPS”), dipalmitoyl sphingomyelin (“DPSP”), and distearoyl sphingomyelin (“DSSP”).

### Claim 37 (depends on 35)

The ultrasound contrast agent of claim 35, wherein the phospholipid is selected from the group consisting of: DSPC, DPPG, DPPE, DSPG, and DSPA.

### Claim 38 (depends on 34)

The ultrasound contrast agent of claim 34, wherein the gas-filled microvesicle comprises two or more components selected form the group consisting of: DSPC, DPPG, DPPA, DSPA, DPPE, DPPG, DSPE-PEG1000, DSPE-PEG2000, palmitic acid and stearic acid.

### Claim 39 (depends on 34)

The ultrasound contrast agent of claim 34, wherein the gas is selected from the group consisting of air, nitrogen, oxygen, CO2, hydrogen, nitrous oxide, a noble or inert gas, a radioactive gas, a hyperpolarized noble gas, a fluorinated gas, a low molecular weight hydrocarbon, a cycloalkane, an alkene, an alkyne, an ether, a ketone, an ester, a halogenated gas and mixtures thereof.

### Claim 40 (depends on 34)

The ultrasound contrast agent of claim 34, wherein the gas comprises a fluorinated gas.

### Claim 41 (depends on 40)

The ultrasound contrast agent of claim 40, wherein the gas is a mixture of C4F10 and nitrogen.

### Claim 42 (depends on 34)

The ultrasound contrast agent of claim 34, further comprising a therapeutic agent.

### Claim 43 (depends on 1)

A composition comprising at least one of the fibrin-binding peptides recited in claim 1 and a therapeutic agent.

### Claim 44 (depends on 1)

A diagnostic imaging method or a method of treatment of clots or thromboembolic disease comprising administering to a mammal a composition comprising at least one of the fibrin-binding peptides recited in claim 1.

### Claim 45 (depends on 44)

The diagnostic imaging or treatment method of claim 44, wherein the composition further comprises a detectable label or therapeutic agent.

### Claim 46 (depends on 44)

The diagnostic imaging or treatment method of claim 44, wherein the detectable label is selected from the group consisting of an optical imaging agent and an ultrasound contrast agent.

### Claim 47 (depends on 44)

The diagnostic imaging or treatment method of claim 44, wherein the composition comprises a therapeutic agent selected from the group consisting of: anticoagulant-thrombolytic or fibrinolytic agents capable of clots lysis, anti-angiogenic agents, cytotoxic agents, and radiotherapeutic agents.

### Claim 48 (depends on 1)

A method for diagnostic imaging or treating pathological conditions associated with clots or thromboembolic disease comprising administering to a mammal a composition comprising at least one of the fibrin-binding peptides recited in claim 1.

### Claim 49 (depends on 48)

The method of claim 48, wherein the composition further comprises a detectable label or therapeutic agent.

### Claim 50 (depends on 49)

The diagnostic imaging or treatment method of claim 49, wherein the detectable label comprises an agent selected from the group consisting of an ultrasound contrast agent and an optical imaging agent.

### Claim 51 (depends on 49)

The treatment method of claim 49, wherein the composition comprises a therapeutic agent selected from the group consisting of: anticoagulant-thrombolytic or fibrinolytic agents capable of clots lysis, anti-angiogenic agents, cytotoxic agents, chemotherapeutic agents, tumoricidal agents, and radiotherapeutic agents.

### Claim 52 (depends on 5)

A method for imaging fibrin-containing tissue in a mammal comprising administering an effective amount of a composition of claim 5 to the mammal and imaging the mammal.

### Claim 53 (depends on 33)

A method for imaging fibrin-containing tissue in a mammal comprising administering an effective amount of a composition of claim 33 to the mammal and subjecting the mammal to ultrasound scanning to image said fibrin-containing tissue.

### Claim 54 (depends on 1)

The fibrin-binding peptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-16, SEQ ID NOS:19-34, SEQ ID NOS:37-40, SEQ ID NOS:47-50, SEQ ID NOS:55-56, SEQ ID NOS:63-74, SEQ ID NOS:77-86, SEQ ID NOS:88-91, SEQ ID NOS:93-94, SEQ ID NOS:96-104, SEQ ID NOS:106-107, SEQ ID NO:109, SEQ ID NOS:111-115, and SEQ ID NOS:117-121.

### Claim 55 (depends on 54)

A diagnostic imaging agent comprising at least one of the fibrin-binding peptides recited in claim 54, wherein said fibrin binding peptide is linked to a detectable label, optionally via a linker or spacer.

### Claim 56 (depends on 55)

The diagnostic imaging agent of claim 55, wherein the agent is adapted for use in a modality selected from ultrasound imaging and optical imaging.

### Claim 57 (depends on 16)

The peptide-phospholipid conjugate of claim 16, selected from the group consisting of SEQ ID NO: 123, SEQ ID NOS:125-128 and SEQ ID NOS:132-133.
